These include four colorectal cancer patients with BRCA1/BRCA2 and a history of breast cancer, one breast cancer patient with MLH1 and a history of endometrial cancer, one colorectal cancer patient with RB1 and a history of retinoblastoma, one colorectal cancer patient with NF1 and features of neurofibromatosis type 1, one prostate cancer patient with FLCN and fibrofolliculomas and lung cysts, and one pancreatic cancer patient with TSC1 and angiomyolipoma, brain lesions, and bilateral renal cysts, which were discovered upon receiving eGT results (Table 1). This evidence concerns the gene FLCN and Familial prostate cancer.